Publications by authors named "Johanna R Zuccoli"

Introduction: Argentina authorized COVID-19 vaccination for adolescents 12 years and older in August 2021, and then for children three years and older in October 2021. Children aged 6 months-2 years received a two-dose regimen beginning July 2022.

Objective: This study aims to analyze the impact of COVID-19 vaccination among children aged 0-17, considering vaccination status and mortality for the 2020-2022 period.

View Article and Find Full Text PDF

Heme enzyme dysfunction causes a group of diseases called porphyrias. Particularly, a decrease in porphobilinogen deaminase, involved in the third step of heme biosynthesis, leads to acute intermittent porphyria (AIP). Considering our previous works demonstrating the multiplicity of brain metabolisms affected by porphyrinogenic agents, this study aimed to elucidate whether they cause any alteration on the mitochondrial respiratory chain.

View Article and Find Full Text PDF

The Multidrug Resistance protein (, ) is involved in the transport of xenobiotics and antiretroviral drugs. Some variants of the gene are of clinical importance; among them, exon 12 (c.1236C>T, rs1128503), 21 (c.

View Article and Find Full Text PDF
Article Synopsis
  • In Argentina, porphyria cutanea tarda (PCT) is linked with HIV infection, but the relationship with HIV and antiretroviral therapy remains unclear.
  • The study examines specific genetic variants that influence drug metabolism and their potential role in the onset of PCT among HIV-infected patients.
  • Findings show that certain gene variants are more frequent in PCT patients, suggesting that genetics, along with antiretroviral therapy, may contribute to the development of PCT in those with HIV.
View Article and Find Full Text PDF

Background: Acute Intermittent Porphyria (AIP) is an inherited disease produced by a deficiency of Porphobilinogen deaminase (PBG-D). The aim of this work was to evaluate the effects of Isoflurane and Sevoflurane on heme metabolism in a mouse genetic model of AIP to further support our previous proposal for avoiding their use in porphyric patients. A comparative study was performed administering the porphyrinogenic drugs allylisopropylacetamide (AIA), barbital and ethanol, and also between sex and mutation using AIP (PBG-D activity 70% reduced) and T1 (PBG-D activity 50% diminished) mice.

View Article and Find Full Text PDF

5-Aminolevulinic acid (ALA) seems to be responsible for the neuropsychiatric manifestations of acute intermittent porphyria (AIP). Our aim was to study the effect of ALA on the different metabolic pathways in the mouse brain to enhance our knowledge about the action of this heme precursor on the central nervous system. Heme metabolism, the cholinergic system, the defense enzyme system, and nitric oxide metabolism were evaluated in the encephalon of CF-1 mice receiving a single (40 mg/kg body mass) or multiple doses of ALA (40 mg/kg, every 48 h for 14 days).

View Article and Find Full Text PDF